Adult

Medimaps Group Deep-tech TBS Software Endorsed by International Experts Working Group To Inform Osteoporosis Management Decisions for The Benefit of The Patient

Retrieved on: 
Wednesday, July 5, 2023
Health, Medical Devices, Technology, Other Health, Software, General Health, Biotechnology, Osteoporosis International, Moyamoya disease, University of Sheffield, Systematic review, Bone, Hip, Chronic kidney disease, DSM-IV codes, Metabolism, Bone fracture, Epidemiology, McCloskey, Type 2 diabetes, Bone density, Woman, IOF, TBS, Trabecula, BMD, Archive, International Osteoporosis Foundation, Dementia, FRAX, Kanis, Patient, Risk, Archives of Osteoporosis, Fracture, Diagnosis, Mortality, WHO, European Society for Medical Oncology, Death, Medical device, Dietary supplement, Dentistry, Adult, Osteoporosis, Ageing, Osteoarthritis

The peer-reviewed article provides endorsed guidance to clinicians looking to enhance the assessment and management of osteoporosis with Medimaps Group TBS iNsight™ software for patient benefit.

Key Points: 
  • The peer-reviewed article provides endorsed guidance to clinicians looking to enhance the assessment and management of osteoporosis with Medimaps Group TBS iNsight™ software for patient benefit.
  • Worldwide, osteoporosis causes more than 8.9 million fractures every year, resulting in an osteoporosis fracture every 3 seconds.
  • The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study.
  • Osteoporosis International, 32, pp.251-25
    Harvey, et al., 2015, Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice, Bone , Volume 78 , Pages 216-224

Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19

Retrieved on: 
Monday, June 26, 2023
Volunteering, Database, Microbiology, SARS-CoV-2, Safety, Efficacy, American Society for Microbiology, COVID-19, Dean, RNA, Professor, Patient, SAN, OTC, National Medical Products Administration, Agency for Toxic Substances and Disease Registry, Therapy, Society, NMPA, Pharmaceutical industry, Adult

During the trial, Ovydso has maintained an excellent safety profile with no Grade 3 toxicities reported.

Key Points: 
  • During the trial, Ovydso has maintained an excellent safety profile with no Grade 3 toxicities reported.
  • Should the Phase 3 trial be successful, we plan to open dialogue with regulatory agencies around the world to discuss paths to approval.
  • With the completion of enrollment for this trial, Sorrento has treated almost 1,450 volunteers and patients.
  • “We are pleased to see that Ovydso has enrolled quickly for a successful completion of enrollment for the phase 3 pivotal trial in China.

New report highlights the best practices for French-language education in Québec.

Retrieved on: 
Wednesday, June 21, 2023
Volunteering, Learning, Unemployment, Education, Government, PERT, Integration, Investment, Plurilingualism, Tourism, Management, Tutoring, Adult

Montreal, June 21, 2023 (GLOBE NEWSWIRE) -- The Provincial Employment Roundtable (PERT) has published a new report entitled “Learning French as an Adult: A Review of Current Best Practices in Adult French-Language Training in Québec”.

Key Points: 
  • Montreal, June 21, 2023 (GLOBE NEWSWIRE) -- The Provincial Employment Roundtable (PERT) has published a new report entitled “Learning French as an Adult: A Review of Current Best Practices in Adult French-Language Training in Québec”.
  • In the report, PERT identifies, analyses and provides recommendations regarding several approaches to adult language education that will significantly improve the delivery of current French language programs in the province.
  • “Our organisation focuses on solutions that address the 4% higher unemployment rate experienced by English speakers in Québec compared to Francophones.
  • Expansion of the availability of affordable adult French-language training programs in order to lower barriers to accessing programs.

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Retrieved on: 
Monday, June 12, 2023
Psychiatry, Translation, Geriatric psychiatry, MidOcean Partners, Healthcare Businesswomen's Association, Research and development, American Board of Psychiatry and Neurology, University, Therapy, Harvard T.H. Chan School of Public Health, CableACE Award, Pharmacokinetics, DSM-IV codes, Head, University of Pittsburgh Medical Center, Chemical & Engineering News, Department of Neurology, Xuanwu hospital, Harvard University, Engineering News-Record, Hospital of the University of Pennsylvania, Development, American Board of Commissioners for Foreign Missions, Science, Chemical substance, Public health, MD, Patient, ABPN, Nature Biotechnology, Hospital, UPMC, Research, FDA, Massachusetts General Hospital, Safety, News, CHDR, Pfizer, Pharmaceutical industry, Adult, Medicine, Ramipril, Neurology

BOSTON, June 12, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Aaron Koenig as Chief Medical Officer. Dr. Koenig will oversee Delix's clinical development programs, team build-out, and broader development strategy as the company advances its psychoplastogen platform of novel disease-modifying therapeutics for serious psychiatric, neurological, and neurodegenerative disorders.

Key Points: 
  • BOSTON, June 12, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Aaron Koenig as Chief Medical Officer.
  • Dr. Koenig joins the company from Sage Therapeutics, where he served most recently as Vice President of Early Medical Science and helped design and oversee clinical-stage programs, including compounds targeting a range of neuropsychiatric and neurodegenerative and disorders.
  • "As Delix navigates its phase I trial for the novel compound DLX-001, Dr. Koenig's experience in early clinical development will be crucial to advancing our novel neuroplasticity-promoting therapeutics," said Delix Therapeutics Head of Research & Development Dr. Eliseo Salinas.
  • A non-hallucinogenic psychoplastogen, DLX-001 is the first of several psychoplastogens in the Delix platform to be approved for human trials.

Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference

Retrieved on: 
Thursday, May 18, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Mayo Clinic, GOSS, PAH, Bio, American Thoracic Society, Pulmonary hypertension, Gossamer, International Conference on Nuclear Disarmament, Oslo, 2008, Patient, Annals of the American Thoracic Society, Poster, Orthostatic hypertension, Conference, Pharmaceutical industry, Adult, Medicine

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24.
  • Dr. Robert Frantz, Director of the Pulmonary Hypertension Clinic and Professor of Medicine at Mayo Clinic will present the data on behalf of the TORREY Study investigators.
  • Presentation Title: Seralutinib Treatment in Adult Subjects with Pulmonary Arterial Hypertension: Results from the TORREY Study
    The presentation and poster will also be made available in the “Posters and Publications” section of the Gossamer Bio website at gossamerbio.com.
  • Following the positive results observed in the TORREY study and discussions with worldwide regulatory authorities, Gossamer plans to initiate a registrational Phase 3 clinical trial in patients with PAH in the third quarter of 2023.

Spruce Biosciences Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Monday, May 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PD, Senior, Investment, Abbott Laboratories, DHEAS, G&A, A4, Patient, Risk, Androstenedione, Research and development, R, SVP, Disease, University, Keck School of Medicine of USC, Clinical trial, Glucocorticoid, CAH, Spruce, Pharmacokinetics, Astex Pharmaceuticals, Growth, Biostatistics, Safety, Puberty, Statistics, Business operations, Adrenocorticotropic hormone, Public health, Administration, PCOS, Adolescence, GBT, ACTH, Therapy, Pfizer, Congenital adrenal hyperplasia, Medicine, Drug, Woman, PES, Annual general meeting, Public expenditure, Novartis, GPC Biotech, Strategic partnership, Female, Pharmaceutical industry, Nursing, Adult, Cycloheximide, Pediatrics, Biometrics, Probability

(Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates.

Key Points: 
  • (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the quarter ended March 31, 2023 and provided corporate updates.
  • “I am pleased by the meaningful progress Spruce made across our clinical and business objectives in the first quarter of 2023.
  • Additionally, we have completed enrollment in our P.O.W.E.R study for PCOS and will be reporting topline data in the third quarter," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences.
  • Spruce remains on track to report topline data from adolescents (cohorts 1 and 2) in the second half of 2023.

Audiology Devices Market Size is Projected To Reach USD 13.1 Billion By 2031 Growing At A CAGR of 6.5% | Valuates Reports

Retrieved on: 
Thursday, May 11, 2023
Hearing aid, Medical device, Ear, Retail, Hearing loss, Hospital, Dental implant, Brain, Research, USD, Government, Projection, Audiology, Hearing, Pediatrics, OTC, Kool-Aid, Artificial intelligence, Growth, Sales, Digital, Abdominal ultrasonography, Geography, Video game, Analog, Adult, Bluetooth

The global audiology devices market size was valued at USD 7.2 billion in 2021 and is projected to reach USD 13.1 billion by 2031, growing at a CAGR of 6.5% from 2022 to 2031.

Key Points: 
  • The global audiology devices market size was valued at USD 7.2 billion in 2021 and is projected to reach USD 13.1 billion by 2031, growing at a CAGR of 6.5% from 2022 to 2031.
  • Expanding technical advancements and the senior population's embrace of cutting-edge technology are further factors that are expected to fuel the Audiology Devices Market.
  • This factor is expected to drive the growth of the Audiology Devices Market
    Expanding technical advancements are also projected to fuel the market for audiology equipment.
  • By geography, North America accounted for approximately two-fifths of the revenue generated by the global market for audiology devices in 2021.

Audiology Devices Market Size is Projected To Reach USD 13.1 Billion By 2031 Growing At A CAGR of 6.5% | Valuates Reports

Retrieved on: 
Thursday, May 11, 2023
Hearing aid, Medical device, Ear, Retail, Hearing loss, Hospital, Dental implant, Brain, Research, USD, Government, Projection, Audiology, Hearing, Pediatrics, OTC, Kool-Aid, Artificial intelligence, Growth, Sales, Digital, Abdominal ultrasonography, Geography, Video game, Analog, Adult, Bluetooth

The global audiology devices market size was valued at USD 7.2 billion in 2021 and is projected to reach USD 13.1 billion by 2031, growing at a CAGR of 6.5% from 2022 to 2031.

Key Points: 
  • The global audiology devices market size was valued at USD 7.2 billion in 2021 and is projected to reach USD 13.1 billion by 2031, growing at a CAGR of 6.5% from 2022 to 2031.
  • Expanding technical advancements and the senior population's embrace of cutting-edge technology are further factors that are expected to fuel the Audiology Devices Market.
  • This factor is expected to drive the growth of the Audiology Devices Market
    Expanding technical advancements are also projected to fuel the market for audiology equipment.
  • By geography, North America accounted for approximately two-fifths of the revenue generated by the global market for audiology devices in 2021.

ASCO Guideline Update for Anxiety and Depression Released

Retrieved on: 
Thursday, April 27, 2023
University of Florida Cancer and Genetics Research Complex, Volunteering, Depression, Education, Quality, CBT, MS, Science, Wastewater treatment, ASCO, Outline, American Society of Clinical Oncology, Patient, Standard of care, Quality of life, Clinical, Health, MBSR, Survivor, Mental health, Society, FCS, Nursing, Anxiety, Adult, Cancer, MD

FORT MYERS, Fla., April 27, 2023 /PRNewswire/ -- A panel of multidisciplinary experts have reviewed previous American Society of Clinical Oncology (ASCO) guidelines for treating anxiety and depression in adult cancer survivors. The Practice Guidelines Implementation Network (PGIN) committee, which includes Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Barry Berman, MD, MS, released updates to the pre-existing guidelines last revised in 2014 in the abstract: "Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update."

Key Points: 
  • Florida Cancer Specialists & Research Institute Medical Oncologist Barry Berman, MD, MS, Serves on ASCO Anxiety & Depression Update Expert Panel
    FORT MYERS, Fla., April 27, 2023 /PRNewswire/ -- A panel of multidisciplinary experts have reviewed previous American Society of Clinical Oncology (ASCO) guidelines for treating anxiety and depression in adult cancer survivors.
  • The Practice Guidelines Implementation Network (PGIN) committee, which includes Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Barry Berman, MD, MS , released updates to the pre-existing guidelines last revised in 2014 in the abstract: "Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update."
  • The panel also draws attention to statistics supporting how depression and anxiety in cancer patients tend to be overlooked and therefore untreated as they are considered a normal reaction to a cancer diagnosis.
  • The guidelines then outline options for treating depression and anxiety as separate issues, as well as offering guidance when both are experienced.

YR Media’s Adult ISH Podcast, Part of Radiotopia from PRX, Talks Schoolyard Beef, Canna-business and Self Love Scams in Season 9

Retrieved on: 
Tuesday, April 25, 2023
Men, LGBTQ+, Foundation, Philanthropy, Podcast, General Entertainment, Social Media, Consumer, Entertainment, Natural Resources, Mobile Entertainment, Cannabis, University, Communications, Education, Teens, Women, Partnership, Alpha, Homelessness, SELF, Culture, Sister, Brain, History, Harvard University, JUST, Generation Z, TRAP, PRX, Boil, Folx-les-Caves, Youth Radio, Apple Podcasts, Amazon Music, BEEF, TuneIn, Heart, BIPOC, Queer, POC, Radiotopia, Social media, Safety, Music, Adult, Turner, Spotify, Stitcher, Season

Adult ISH is produced by YR Media and brought to audiences in partnership with Radiotopia from PRX , a network of independent podcasts.

Key Points: 
  • Adult ISH is produced by YR Media and brought to audiences in partnership with Radiotopia from PRX , a network of independent podcasts.
  • This season, the dynamic duo dives into stories of cannabis, self-love shams, the joy of drag, and grudges.
  • Turner and French bring on teen and twenty-something co-hosts, authors, and up-and-coming stars in Adult ISH’s most boundary-pushing season yet.
  • “When it comes to amplifying previously unheard and underserved perspectives, the Adult ISH team does not miss,” said Kyles.